Drugs /

gen1044

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD3/anti-5T4 bispecific antibody GEN1044 simultaneously targets and binds to CD3 expressed on T-cells and 5T4 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.

Clinical Trials

View Clinical Trials for gen1044

Gen1044 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating gen1044, 1 is phase 1/phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for gen1044 clinical trials.

Bladder carcinoma, breast carcinoma, and esophageal carcinoma are the most common diseases being investigated in gen1044 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gen1044
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gen1044 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-cd3/anti-5t4 bispecific antibody gen1044, gen-1044, gen 1044, duobody-cd3x5t4
NCIT ID [1]:
C173369

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.